Abstract
The treatment of glioma remains one of the most interesting topics in neurooncology. Glioblastoma multiforme is the most aggressive and prevalent malignant brain tumor. Nowadays, technologies and new tools are helping the neurosurgeons to define a tailored surgery. However, there are few pharmaceutical strategies in operated and nonoperated patients. There are still few anticancer drugs approved by FDA and EMA. Moreover, these drugs are not so effective and have a lot of side effects due to their toxicity. Nanoparticles are a new strategy which could help to create and carry new drugs. In fact, NPs improve the pharmacokinetic properties of anticancer drugs, reduce side-effects, and increase drug half-life and its selectivity. Nanoparticle drug delivery system has been studied for targeting different molecular biomarkers and signaling pathways. Furthermore, the first problem of anticancer drugs in the treatment of gliomas is penetrating the blood brain barrier which represents an insurmountable wall for most of synthetic and natural particles. In the last 15 years, a lot of researches tried to design a perfect nanoparticle both able to cross blood–brain barrier and to selectively target glioma cells, unfortunately, without great results. In vivo human trials are still ongoing and many of them have already failed. In this chapter we evaluate the effectiveness of nanotechnologies in the treatment of brain tumors. There is not yet, currently, a nanoparticle drug designed for the treatment of gliomas approved by FDA and EMA. Advancements in discovery of molecular characteristics of tumors lead to the development of targeted nanoparticles that are tested in numerous in vitro and in vivo studies on gliomas. Novel and repurposed drugs, as well as novel drug combinations, have also been already studied but those are not included in this chapter because the carried drugs (active substances) are not included among the approved anticancer drug used in the treatment of gliomas.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aktaş Y et al (2005) Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. Bioconjugate Chem 16:1503–1511. https://doi.org/10.1021/bc050217o
Battaglia L et al (2015) Bevacizumab loaded solid lipid nanoparticles prepared by the coacervation technique: preliminary in vitro studies. Nanotechnology 26:255102. https://doi.org/10.1088/0957-4484/26/25/255102
Belhadj Z, Zhan C, Ying M, Wei X, Xie C, Yan Z, Lu W (2017) Multifunctional targeted liposomal drug delivery for efficient glioblastoma treatment. Oncotarget 8:66889–66900. https://doi.org/10.18632/oncotarget.17976
Byrne JD, Betancourt T, Brannon-Peppas L (2008) Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 60:1615–1626. https://doi.org/10.1016/j.addr.2008.08.005
Caffo M et al (2017) Modulation of Dkk-3 and claudin-5 as new therapeutic strategy in the treatment of meningiomas. Oncotarget 8:68280–68290. https://doi.org/10.18632/oncotarget.20047
Cardoso FL, Brites D, Brito MA (2010) Looking at the blood-brain barrier: molecular anatomy and possible investigation approaches. Brain Res Rev 64:328–363. https://doi.org/10.1016/j.brainresrev.2010.05.003
Caruso G, Caffo M, Raudino G, Alafaci C, Salpietro FM, Tomasello F (2010) Antisense oligonucleotides as innovative therapeutic strategy in the treatment of high-grade gliomas. Recent Pat CNS Drug Discov 5:53–69. https://doi.org/10.2174/157488910789753503
Caruso G et al (2011) Could nanoparticle systems have a role in the treatment of cerebral gliomas? Nanomed Nanotechnol Biol Med 7:744–752. https://doi.org/10.1016/j.nano.2011.02.008
Caruso G, Merlo L, Caffo M (2014) Innovative brain tumor therapy,vol 67. Woodhead Publishing
Caruso G, Merlo L, Tot E, Pignataro C, Caffo M (2017) Chapter 6-nanotechnology and the new frontiers of drug delivery in cerebral gliomas. In: Grumezescu AM (ed) Nano-and microscale drug delivery systems. Elsevier, pp 95–112. https://doi.org/10.1016/B978-0-323-52727-9.00006-6
Chen C et al (2017) Peptide-22 and Cyclic RGD functionalized liposomes for glioma targeting drug delivery overcoming BBB and BBTB. ACS Appl Mater Interfaces 9:5864–5873. https://doi.org/10.1021/acsami.6b15831
Dubin CH (2004) Special delivery. Mech Eng 126:S10
Fang C et al (2015) Temozolomide nanoparticles for targeted glioblastoma therapy. ACS Appl Mater Interfaces 7:6674–6682. https://doi.org/10.1021/am5092165
Feng X et al (2015) Multi-targeting peptide-functionalized nanoparticles recognized vasculogenic mimicry tumor neovasculature, and glioma cells for enhanced anti-glioma therapy. ACS Appl Mater Interfaces 7:27885–27899. https://doi.org/10.1021/acsami.5b09934
Furnari FB et al (2007) Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Develop 21:2683–2710. https://doi.org/10.1101/gad.1596707
Ganipineni LP et al (2018) Magnetic targeting of paclitaxel-loaded poly(lactic-co-glycolic acid)-based nanoparticles for the treatment of glioblastoma. Int J Nanomed 13:4509–4521. https://doi.org/10.2147/ijn.s165184
Garrett CR, Eng C (2011) Cetuximab in the treatment of patients with colorectal cancer. Expert Opin Biol Ther 11:937–949. https://doi.org/10.1517/14712598.2011.582464
Gaspar LE, Fisher BJ, Macdonald DR, LeBer DV, Halperin EC, Schold Jr SC, Cairncross JG (1992) Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. Int J Radiat Oncol Biol Phys 24:55–57. https://doi.org/10.1016/0360-3016(92)91021-e
Hasselbalch B et al (2010) Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 12:508–516. https://doi.org/10.1093/neuonc/nop063
Huang S et al (2013) Tumor-targeting and microenvironment-responsive smart nanoparticles for combination therapy of antiangiogenesis and apoptosis. ACS Nano 7:2860–2871. https://doi.org/10.1021/nn400548g
Jiang P et al (2014) Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs. J Transl Med 12:13. https://doi.org/10.1186/1479-5876-12-13
Kaluzova M, Bouras A, Machaidze R, Hadjipanayis CG (2015) Targeted therapy of glioblastoma stem-like cells and tumor non-stem cells using cetuximab-conjugated iron-oxide. Nanoparticles Oncotarget 6:8788–8806. https://doi.org/10.18632/oncotarget.3554
Ke W et al (2009) Gene delivery targeted to the brain using an angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. Biomaterials 30:6976–6985. https://doi.org/10.1016/j.biomaterials.2009.08.049
Kumar P et al (2007) Transvascular delivery of small interfering RNA to the central nervous system. Nature 448:39–43. https://doi.org/10.1038/nature05901
Kwon GS (2003) Polymeric micelles for delivery of poorly water-soluble compounds. Crit Rev Ther Drug Carrier Syst 20:357–403. https://doi.org/10.1615/critrevtherdrugcarriersyst.v20.i5.20
Lakkadwala S, Singh J (2019) Co-delivery of doxorubicin and erlotinib through liposomal nanoparticles for glioblastoma tumor regression using an in vitro brain tumor model Colloids and surfaces B. Biointerfaces 173:27–35. https://doi.org/10.1016/j.colsurfb.2018.09.047
Larsen AK, Ouaret D, El Ouadrani K, Petitprez A (2011) Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis. Pharmacol Ther 131:80–90. https://doi.org/10.1016/j.pharmthera.2011.03.012
Li Y, He H, Jia X, Lu WL, Lou J, Wei Y (2012) A dual-targeting nanocarrier based on poly(amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas. Biomaterials 33:3899–3908. https://doi.org/10.1016/j.biomaterials.2012.02.004
Liao L et al (2014) Subchronic toxicity and immunotoxicity of MeO-PEG-poly(D,L-lactic-co-glycolic acid)-PEG-OMe triblock copolymer nanoparticles delivered intravenously into rats. Nanotechnology 25:245705. https://doi.org/10.1088/0957-4484/25/24/245705
Lu W, Tan YZ, Hu KL, Jiang XG (2005) Cationic albumin conjugated pegylated nanoparticle with its transcytosis ability and little toxicity against blood-brain barrier. Int J Pharm 295:247–260. https://doi.org/10.1016/j.ijpharm.2005.01.043
Martins SM, Sarmento B, Nunes C, Lúcio M, Reis S, Ferreira DC (2013) Brain targeting effect of camptothecin-loaded solid lipid nanoparticles in rat after intravenous administration. Eur J Pharm Biopharm off J Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik eV 85:488–502. https://doi.org/10.1016/j.ejpb.2013.08.011
Qin Y et al (2010) In vitro and in vivo investigation of glucose-mediated brain-targeting liposomes. J Drug Target 18:536–549. https://doi.org/10.3109/10611861003587235
Quader S et al (2017) cRGD peptide-installed epirubicin-loaded polymeric micelles for effective targeted therapy against brain tumors. J Controlled Release Off J Controlled Release Soc 258:56–66. https://doi.org/10.1016/j.jconrel.2017.04.033
Rapoport N, Marin AP, Timoshin AA (2000) Effect of a polymeric surfactant on electron transport in HL-60 cells. Arch Biochem Biophys 384:100–108. https://doi.org/10.1006/abbi.2000.2104
Sarisozen C, Dhokai S, Tsikudo EG, Luther E, Rachman IM, Torchilin VP (2016) Nanomedicine based curcumin and doxorubicin combination treatment of glioblastoma with scFv-targeted micelles: In vitro evaluation on 2D and 3D tumor models. Eur J Pharm Biopharm Off J Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV 108:54–67. https://doi.org/10.1016/j.ejpb.2016.08.013
Schucht P et al (2012) Gross total resection rates in contemporary glioblastoma surgery: results of an institutional protocol combining 5-aminolevulinic acid intraoperative fluorescence imaging and brain mapping. Neurosurgery 71:927–935; discussion 935–926. https://doi.org/10.1227/NEU.0b013e31826d1e6b
Snuderl M et al (2011) Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 20:810–817. https://doi.org/10.1016/j.ccr.2011.11.005
Suk JS, Xu Q, Kim N, Hanes J, Ensign LM (2016) PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev 99:28–51. https://doi.org/10.1016/j.addr.2015.09.012
Ulbrich K, Hekmatara T, Herbert E, Kreuter J (2009) Transferrin and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur J Pharm Biopharm Off J Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV 71:251–256. https://doi.org/10.1016/j.ejpb.2008.08.021
Veiseh O, Gunn JW, Kievit FM, Sun C, Fang C, Lee JS, Zhang M (2009) Inhibition of tumor-cell invasion with chlorotoxin-bound superparamagnetic nanoparticles. Small (Weinheim an der Bergstrasse, Germany) 5:256–264. https://doi.org/10.1002/smll.200800646
Veiseh M et al (2007) Tumor paint: a chlorotoxin: Cy5.5 bioconjugate for intraoperative visualization of cancer foci. Cancer Res 67:6882–6888. https://doi.org/10.1158/0008-5472.can-06-3948
Wang K, Kievit FM, Jeon M, Silber JR, Ellenbogen RG, Zhang M (2015) Nanoparticle-mediated target delivery of TRAIL as gene therapy for glioblastoma. Adv Healthc Mater 4:2719–2726. https://doi.org/10.1002/adhm.201500563
Wei X, Chen X, Ying M, Lu W (2014) Brain Tumor-targeted drug delivery strategies. Acta Pharmaceutica Sinica B 4:193–201. https://doi.org/10.1016/j.apsb.2014.03.001
Wilson B, Lavanya Y, Priyadarshini SR, Ramasamy M, Jenita JL (2014) Albumin nanoparticles for the delivery of gabapentin: preparation, characterization and pharmacodynamic studies. Int J Pharm 473:73–79.https://doi.org/10.1016/j.ijpharm.2014.05.056
Zhang X, Bu XY, Zhen HN, Fei Z, Zhang JN, Fu LA (2000) Expression and localisation of urokinase-type plasminogen activator gene in gliomas. J Clin Neurosci off J Neurosurg Soc Australas 7:116–119. https://doi.org/10.1054/jocn.1999.0161
Zhang B et al (2015) UPA-sensitive ACPP-conjugated nanoparticles for multi-targeting therapy of brain glioma. Biomaterials 36:98–109. https://doi.org/10.1016/j.biomaterials.2014.09.008
Zhang TT, Li W, Meng G, Wang P, Liao W (2016) Strategies for transporting nanoparticles across the blood-brain barrier. Biomater Sci 4:219–229. https://doi.org/10.1039/c5bm00383k
Zhang Y et al (2018) Cell-permeable NF-Κb inhibitor-conjugated liposomes for treatment of glioma. J Controlled Release off J Controlled Release Soc 289:102–113. https://doi.org/10.1016/j.jconrel.2018.09.016
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Caffo, M. et al. (2023). The Role of Nanotechnologies in Brain Tumors. In: Rezaei, N., Hanaei, S. (eds) Human Brain and Spinal Cord Tumors: From Bench to Bedside. Volume 1. Advances in Experimental Medicine and Biology, vol 1394. Springer, Cham. https://doi.org/10.1007/978-3-031-14732-6_11
Download citation
DOI: https://doi.org/10.1007/978-3-031-14732-6_11
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-14731-9
Online ISBN: 978-3-031-14732-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)